Trial Profile
Phase II trial of induction gefitinib followed by cisplatin and docetaxel with concurrent radiotherapy in locally advanced non-small cell lung cancer with EGFR activating mutation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Docetaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 08 Apr 2022 Status changed from active, no longer recruiting to completed.
- 20 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2014 Planned number of patients changed from 46 to 21.